New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 27, 2021 - Biohaven announced the FDA approval of Nurtec ODT (rimegepant), for the preventive treatment of episodic migraine in adults.
Download PDF
Return to publications
